Media coverage about Spero Therapeutics (NASDAQ:SPRO) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Spero Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.7521532142989 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
SPRO has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $27.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Monday, April 30th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Tuesday, April 3rd. Finally, HC Wainwright initiated coverage on shares of Spero Therapeutics in a report on Friday, May 11th. They set a “buy” rating and a $28.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Spero Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.00.
Spero Therapeutics traded up $0.48, reaching $15.13, during trading on Monday, according to Marketbeat.com. 133,000 shares of the stock were exchanged, compared to its average volume of 49,081. The company has a market cap of $210.51 million and a price-to-earnings ratio of -0.85. Spero Therapeutics has a twelve month low of $9.66 and a twelve month high of $19.00.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.